Title : The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia.

Pub. Date : 2018 May 31

PMID : 29857559






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia. RG7388 transformed mouse 3T3 cell double minute 2 Mus musculus
2 The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia. RG7388 transformed mouse 3T3 cell double minute 2 Mus musculus
3 Here we assessed the MDM2 antagonist idasanutlin and the MEK1 inhibitor cobimetinib as single agents and in combination in a variety of AML cell lines and primary AML blast cells for their ability to induce apoptosis and cell death. RG7388 transformed mouse 3T3 cell double minute 2 Mus musculus
4 Our data indicate that AML cells with normal karyotype (NK) and wild-type status of TP53 with elevated FLT3 and MDM2 expression emerge to be most sensitive to the combined treatment with cobimetinib and idasanutlin. RG7388 transformed mouse 3T3 cell double minute 2 Mus musculus
5 FLT3 and MDM2 are biomarkers for treatment response to idasanutlin and cobimetinib in AML. RG7388 transformed mouse 3T3 cell double minute 2 Mus musculus